Rechargeable batteries that last longer and recharge more rapidly
Researchers at the Swiss Paul Scherrer Institute PSI and ETH Zurich have developed a simple and cost-effective procedure for significantly enhancing the performance of conventional Li-ion rechargeable batteries. Whether in wristwatches, smartphones, laptops or cars, the use of rechargeable batteries will be optimized in all areas of application, considerably extending storage capacity as well as cutting down charging times.
To starve a tumour
PSI researcher Kurt Ballmer-Hofer is concerned with the question of how tumours could be starved by preventing the development of blood vessels. After 40 years of research that yielded many fundamental insights about the formation of blood vessels, one of the key molecules has been found; further research is expected to enable clinical applications.
Turning Electricity into Gas – and back into Electricity
As capacities for producing solar and wind energy increase, integrating these into the existing energy system is becoming more of a challenge. The ESI platform is testing methods for successful integration. The answer: storing surplus energy as gas.
High-performance catalytic converters for natural-gas vehicles
Natural-gas vehicles are on the way, and they need catalytic converters for the exhaust too. While work is under way at Empa, the Swiss Federal Laboratories for Materials Testing and Research, to optimise natural-gas engines and catalytic converters, the PSI is specialising in research methods that enable very precise observation of catalytic converters. For this work, the PSI researchers have now developed a universal measurement chamber in which catalytic converters can be studied with a variety of different analytical methods, yet always under the same conditions.
One atom at a time
At the PSI, the Heavy Elements Research Group explores the exotic, unstable atoms at the end of the periodic table of elements. The dream: to discover one day the island of stability that could exist beyond the elements charted so far on the chemists' map.
Zebra - a new instrument for the PSI
Interview with Oksana ZaharkoNew scientific questions demand ever better experimental equipment. In this interview, PSI researcher Oksana Zaharko reports on the challenges of setting up a new instrument for research with neutrons.
Present-day measurements yield insights into clouds of the past
Researchers have shown how fine particles are formed from natural substances in the atmosphere. These findings will improve our knowledge about clouds in the pre-industrial era and thus will contribute to a more accurate understanding of both the past and future evolution of our climate.
Structure of the ESI Platform
The road to a sustainable energy future leads through the integration of new renewable energy sources, from the sun, the wind, or biomass. Using the Energy System Integration or ESI Platform, research and industry can test promising approaches in all their complex connections and interrelations.
Experiment in a hovering droplet
At the PSI, the exact structure of proteins is deciphered in the standard way, with X-rays. Now two PSI researchers have used a clever trick to advance this method further: Instead of pinning down the proteins, they are studying them within a levitating drop of liquid.
Trees Trade Carbon Among Each Other
Forest trees use carbon not only for themselves; they also trade large quantities of it with their neighbours. The extensive carbon trade among trees – even among different species – is conducted via symbiotic fungi in the soil.
Hitting cancer from the inside
Researchers at the Paul Scherrer Institute PSI are now investigating a new method to channel radioactive substances directly into the nucleus of a cancer cell. Through this approach, the radiation source remains inside the cell and works in a more targeted way, because it gets closer to the cell's genetic information.
Using methane rather than flaring it
Chemists at ETH Zurich and the Paul Scherrer Institute have found a new, direct way to convert gaseous methane into liquid methanol. This offers industry the interesting prospect of using the gas, rather than simply burning it off, as is currently the case.
New particle could form the basis of energy-saving electronics
The Weyl fermion, just discovered in the past year, moves through materials practically without resistance. Now researchers are showing how it could be put to use in electronic components.
From the Higgs boson to new drugs
A picture-perfect example of how basic research makes concrete contributions to the economy is the company DECTRIS — a PSI spin-off founded in 2006 and already highly successful. The latest development from DECTRIS is a detector called EIGER, which is used for X-ray measurements at large research facilities. There EIGER contributes, among other things, to the search for new drugs.
Five hundred thousand times less likely than winning the lottery
Measuring the rarity of a particle decayIn the so-called MEG experiment at the PSI, researchers are searching for an extremely rare decay signature from a certain kind of elementary particles known as muons. More precisely, they are quantifying its improbability. According to their latest number, this decay occurs less than once in 2.4 trillion events. By means of this result, theoretical physicists can sort out which of their approaches to describing the universe will hold up against reality.
Medicines made to order with pinpoint precision
At PSI, scientists are developing new medicines against cancer. These contain radioactive substances that can be injected into the patients and thus make their way to the tumour. There, in direct contact, their radiation should destroy the cancer cells. Before such a radioactive medicine can be tested on patients in the first clinical trials, however, its safety must be guaranteed to ensure that the patient will not be harmed. Therefore every agent is produced at the PSI under sterile conditions and tested – separately for each patient, and only on the doctor's order.
Transport von aufgelösten Plutoniumlager des Bundes in die USA ist erfolgt
Im Januar und Februar 2016 wurden unter strengen Sicherheitsvorkehrungen rund 20kg Plutonium im Eigentum des Bundes in die USA transportiert. Es handelt sich dabei um Material, das seit den 1960er Jahren auf dem Areal des heutigen Paul Scherrer Instituts (PSI) gelagert worden war. Das Plutonium stammte aus wiederaufbereiteten Brennstäben des von 1960 bis 1977 betriebenen Forschungsreaktors Diorit. Der Bundesrat beschloss 2014 im Rahmen des Nuclear Security Summit-Prozesses, das Plutoniumlager aufzulösen und damit zur weltweiten Sicherung von Nuklearmaterial beizutragen.This news release is only available in French and German.
Cooperation with nature
With SwissFEL, a new landscape takes shapeBarely completed, the building housing the X-ray free-electron laser SwissFEL has disappeared again beneath a mound of earth. Since then, planting and landscaping have been under way on and around this major research facility of the Paul Scherrer Institute PSI. Its special location, in a forest, demands that SwissFEL be integrated in an environmentally appropriate way. So the facility is, from the outside, nearly invisible. And rare animals and plants have gained new living space.
Decommissioning of the research reactor Proteus
Start of the public examination period for decommissioning of the nuclear facility Proteus at the Paul Scherrer Institute PSIThe nuclear research facility Proteus is a so-called zero-power reactor. In service, the thermal output of the reactor was limited to a maximum of 1 kW. That means this is an experimental reactor that was run at a power level so low that it did not require cooling. Proteus went into service in 1968. The PSI would like to decommission the facility. The decommissioning project is now being publicly announced in the legally prescribed, official publications.
Developing a new drug against thyroid cancer
Researchers at the Paul Scherrer Institute PSI have developed a drug to trace and treat a particularly malignant strain of thyroid cancer more effectively. One advantage of the new drug is that it can be used to treat a strain of thyroid cancer where the established treatment is ineffective. The researchers at PSI have developed the new drug to such an extent that an initial study conducted on cancer patients at the University Hospital Basel can now get underway.